Future of Antibody Research

Antibody-drug conjugates (ADCs) are future of antibody research -edge biopharmaceuticals that link specific antibodies to potent cytotoxic agents through chemically constructed linkers. This enables the targeting of tumor cells with high specificity and reduces off-target toxicity that has limited traditional chemotherapy drugs. By 2024, over 15 ADCs have been approved by the FDA, with approximately 42% targeting oncology indications [8]. The design of ADCs requires stringent criteria for the selection of target antibodies and their corresponding linker. Ideally, the targeted antibody should have adequate affinity for its antigen, preventing premature release of cytotoxic agent in systemic circulation, and exhibit sufficient solubility to efficiently infiltrate tumor tissues [9].

The ideal linker should be stable in systemic circulation, enabling ADCs to retain a stable connection between the target antibody and cytotoxic payload during its passage through the bloodstream to the tumor site. Furthermore, the linker should also bind the hydrophilic/lipophilic characteristics of effective payloads to promote their efficient internalization and avoid premature release in healthy tissues. Moreover, excessive hydrophobicity promotes aggregation of ADCs under physiological conditions and enhances their sensitivity to immune clearance, leading to suboptimal ADC pharmaceutical stability and diminished therapeutic efficacy [10].

Common Challenges in ELISA Test Result Interpretation and How to Overcome Them

Site-specific coupling technologies enable the modification or engineering of mAbs with unique functional groups for the selective attachment of cytotoxic agents. These include engineered cysteine (Thio-mab) coupling, unnatural amino acid coupling, and enzymatic modification of formylglycine residues using transglutaminase or formylglycine-generating enzymes [111]. Cleavable linkers exploit the distinct intracellular environments present in the tumor microenvironment to selectively release cytotoxic agents from the mAb upon exposure to an acidic pH, specific redox conditions, or enzymatic activity.